FINAL |
3 October 2012
|
(“Sareum” or “the Company”)
Final Results
Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery business, is pleased to announce its final results for the year ended 30 June 2012.
Operational Highlights
o nomination of a pre-clinical development candidate from its Chk1 programme
o positive in vivo results from its TYK2 programme
Financial Highlights
Tim Mitchell, Chief Executive Officer of the Company, said: “We have made considerable progress during the year in a number of key areas including seeing positive in-vivo results for our TYK2 programme and the nomination of a development candidate for Chk1.
We continue to focus our efforts on commercialising our research programmes to fuel the future growth of the Company and I remain confident that these efforts will result in the conclusion of one such deal this calendar year.
The addition of the £4 million SEDA financing facility gives us considerable flexibility in funding further development work; hence Sareum is well positioned for the next stage in its corporate development.”
Sareum Holdings plc |
|
Tim Mitchell |
01223 497 700 |
Merchant Securities Limited (Nomad) |
|
Simon Clements |
020 7628 2200 |
Hybridan LLP (Broker) |
|
Claire Noyce / Deepak Reddy |
020 7947 4350 |
The Communications Portfolio (Media enquiries) |
|
Philip Ranger / Caolan Mahon |
020 7536 2028 / 2029 |
philip.ranger@communications-portfolio.co.uk |
|
Annual Results 2012 available as PDF document: Annual Results 2012